BioSpace News Archive

Oncopeptides AB announced measures the company is taking in response to the global spread of the novel coronavirus pandemic.

PMT Partners announced up to 1,000 Oxylators ® emergency ventilation – resuscitation devices are available immediately for clinical use. The Oxylator is a small portable ventilation - resuscitation device that runs on compressed oxygen or air. “Oxylators can serve a variety of roles in hospital and pre-hospital settings,” sa

PALO ALTO, Calif. , March 20, 2020 /PRNewswire/ -- The COVID Q&A bot answers questions on the coronavirus symptoms, prevention, and treatment, among other things. It helps people concerned about the coronavirus outbreak to quickly get answers to their burning questions. The bot relies on the information from the Centers for Disease Control and Prevention (CDC) and the Worl

Directive mandates reimbursement coverage of Tumor Treating Fields for patients with newly diagnosed glioblastoma by the compulsory health insurance system

CABENUVA™ offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression

AIkido Pharma Incorporated (Nasdaq: AIKI) today announced the addition of Andreas Typaldos to the Company’s Advisory Board.

MMS Holdings (MMS) – an award-winning, data-focused CRO – announced today that it is offering a USD1M award toward the development of a vaccine for COVID-19, also known as the coronavirus.

The Feinstein Institutes for Medical Research, the research arm of Northwell Health, announced today the enrollment of three clinical trials in the ongoing effort to combat COVID-19, the novel coronavirus.

As part of the U.S. Food and Drug Administration’s ongoing commitment to address the coronavirus (COVID-19) pandemic, the agency has issued two guidance documents to communicate its policy for the temporary manufacture of certain alcohol-based hand sanitizer products.

Valeritas Holdings, Inc. (OTCPK: VLRXQ) (“Valeritas” or the “Company”), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, today announced that the U.S. Bankruptcy Court for the District of Delaware (the “Court”) approved the sale of substantially all of the business to Zealand Pharma A/S (NASDAQ: ZEAL) (“Zealand”), a Denmark-based biotechnology company